FDAnews
www.fdanews.com/articles/73367-dor-biopharma-announces-positive-interim-results-from-rivax-trial

DOR BioPharma Announces Positive Interim Results From RiVax Trial

June 15, 2005

DOR BioPharma has announced positive interim results from its ongoing Phase I clinical trial of RiVax, its vaccine against ricin toxin.

The Phase I clinical trial of RiVax represents the first ricin toxin vaccine ever to be clinically tested in humans and is being conducted by DOR's academic partner, a group led by Ellen Vitetta at the University of Texas Southwestern Medical Center at Dallas.

In the rising-dose, open-label trial, three cohorts of five normal volunteers each have been dosed three times with 10, 33 and 100 mcg. These interim data are from the first two lower dose cohorts of volunteers.

Early results demonstrate that the vaccine is safe and immunogenic after immunization with three monthly injections of vaccine, with volunteers developing antibodies. This is the first indication that a ricin toxin vaccine elicits immune responses and predicts that humans can be protected against ricin exposure. Antibody data from all three cohorts is expected in the next several months.